Related Experiment Video
Updated: Nov 18, 2025
09:38
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
8.2K
Almonertinib-induced interstitial lung disease: A case report
Ting Jiang1, Yiyang Luo1, Binbin Wang2
1First Clinical Medical College, Zhejiang Chinese Medical University.
Medicine
|February 6, 2021
Summary
This study reports the first case of interstitial lung disease (ILD) caused by Almonertinib, a third-generation EGFR-TKI, in an elderly lung adenocarcinoma patient. Prompt treatment with methylprednisolone led to symptom resolution and ILD remission.
Area of Science:
- Oncology
- Pulmonology
- Pharmacology
Background:
- Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are effective in treating non-small cell lung cancer, particularly lung adenocarcinoma.
- Interstitial lung disease (ILD) is a known fatal side effect of some EGFR-TKIs.
- Almonertinib (HS-10296) is a third-generation EGFR-TKI, and ILD has not been previously reported as a side effect.
Purpose of the Study:
- To report the first case of Almonertinib-induced interstitial lung disease (ILD).
- To highlight the potential for this rare but severe side effect in patients treated with Almonertinib.
Main Methods:
- A case study of a 70-year-old female with EGFR 19DEL-mutated lung adenocarcinoma and intracranial metastasis.
- Treatment with Almonertinib 110 mg orally as first-line therapy.
- Diagnosis of ILD based on symptoms (chest tightness, shortness of breath, cough), CT scans, and exclusion of other causes after 3 months of treatment.
Main Results:
- The patient developed symptoms suggestive of ILD three months after starting Almonertinib.
- Chest CT revealed diffuse bilateral ILD.
- Discontinuation of Almonertinib and treatment with methylprednisolone resulted in complete symptom resolution and ILD remission on CT scans.
Conclusions:
- Almonertinib, a third-generation EGFR-TKI, can induce interstitial lung disease (ILD).
- This represents a rare but potentially fatal adverse event that requires clinical vigilance.
- Healthcare providers should monitor patients closely for signs of ILD when prescribing Almonertinib.
